Cancer clinical trials in the region Pays de la Loire
413 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Prostate cancer
#NCT05939414
#2022-502956-29-00
Required disease stage
Biochemical recurrence
Metastatic Hormone-sensitive
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Surgery
Radiotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Hormone therapy
7 recruiting sites
Novartis
Phase 3
Kidney cancer
#NCT06364631
#2023-503317-29-00
Required histologic types
Clear cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required IMDC scores
0
1 or 2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
36 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Breast cancer
#NCT05232916
#2023-504323-25-01
Required HER2 statuses
HER2 Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
22 recruiting sites
Greenwich LifeSciences, Inc.
Phase 3
Lung cancer
#NCT06875310
#2024-515698-85-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Lung cancer
#NCT05692999
#2023-503481-23-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
28 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Breast cancer
#NCT05696626
#2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.
Phase 3
Lung cancer
#NCT05211895
#2023-506891-28-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Radiotherapy
Excluded genetic anomalies
ALK
EGFR
11 recruiting sites
AstraZeneca
Phase 3
Prostate cancer
#NCT05116475
#2024-517285-41-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3
Prostate cancer
#NCT06276465
#2023-507482-26-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Radiotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
10 recruiting sites
UNICANCER
Phase 3
Colon cancer
Rectal cancer
#NCT05253651
#2024-514180-25-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
NRAS
18 recruiting sites
Seagen